Who is sponsoring NCT02797847?

NCT02797847 is sponsored by Alnylam Pharmaceuticals.

What drugs are being tested in NCT02797847?

Interventions in NCT02797847: ALN-TTRSC02, Sterile Normal Saline (0.9% NaCl).

What condition does NCT02797847 study?

NCT02797847 studies Transthyretin-mediated Amyloidosis (ATTR Amyloidosis).

Is NCT02797847 still recruiting?

NCT02797847 is currently completed. Last updated 21 September 2018.

Last reviewed 2018-09-21 · How we verify

NCT02797847

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Safety and Tolerability Study of an Investigational Drug, ALN-TTRSC02, in Healthy Subjects

Completed Phase 1 Last updated 21 September 2018

What this trial tests

Phase 1 trial testing ALN-TTRSC02 in Transthyretin-mediated Amyloidosis (ATTR Amyloidosis) in 80 participants. Completed in 12 January 2018.

Timeline

7 June 2016

Primary endpoint
12 January 2018

12 January 2018

Quick facts

Lead sponsor	Alnylam Pharmaceuticals
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	80
Start date	7 June 2016
Primary completion	12 January 2018
Estimated completion	12 January 2018
Sites	1 location across United Kingdom

Drugs / interventions tested

ALN-TTRSC02 — full drug profile →
Sterile Normal Saline (0.9% NaCl) — full drug profile →

Conditions studied

Transthyretin-mediated Amyloidosis (ATTR Amyloidosis) — all drugs for Transthyretin-mediated Amyloidosis (ATTR Amyloidosis) →

Sponsor

Alnylam Pharmaceuticals — full company profile →

Who can join

Adults 18 to 65, any sex, with Transthyretin-mediated Amyloidosis (ATTR Amyloidosis). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine the safety, tolerability, pharmacokinetics and pharmacodynamics of ALN-TTRSC02 in healthy subjects.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Therapeutic siRNA: state of the art.
Hu B, Zhong L, Weng Y, Peng L, et al · · 2020 · cited 991× · PMID 32561705 · DOI 10.1038/s41392-020-0207-x
Preclinical and Clinical Advances of GalNAc-Decorated Nucleic Acid Therapeutics.
Huang Y. · · 2017 · cited 205× · PMID 28325278 · DOI 10.1016/j.omtn.2016.12.003
Bioconjugated Oligonucleotides: Recent Developments and Therapeutic Applications.
Benizri S, Gissot A, Martin A, Vialet B, et al · · 2019 · cited 161× · PMID 30608140 · DOI 10.1021/acs.bioconjchem.8b00761
Pathophysiology and Therapeutic Approaches to Cardiac Amyloidosis.
Griffin JM, Rosenblum H, Maurer MS. · · 2021 · cited 130× · PMID 33983835 · DOI 10.1161/circresaha.121.318187
Improved Nucleic Acid Therapy with Advanced Nanoscale Biotechnology.
Weng Y, Huang Q, Li C, Yang Y, et al · · 2020 · cited 72× · PMID 31927331 · DOI 10.1016/j.omtn.2019.12.004
Inhaled siRNA Formulations for Respiratory Diseases: From Basic Research to Clinical Application.
Fan Y, Yang Z. · · 2022 · cited 10× · PMID 35745766 · DOI 10.3390/pharmaceutics14061193
RNA Interference Therapeutics for Hereditary Amyloidosis: A Narrative Review of Clinical Trial Outcomes and Future Directions.
Dave P, Anand P, Kothawala A, Srikaram P, et al · · 2024 · cited 5× · PMID 39044869 · DOI 10.7759/cureus.62981
C16-siRNAs in Focus: Development of ALN-APP, a Promising RNAi-Based Therapeutic for Alzheimer's Disease.
Titze-de-Almeida R, Oliveira Gomes GM, Santos TCD, Titze-de-Almeida SS. · · 2025 · PMID 41599628 · DOI 10.3390/ph19010026

Verify or expand the search:

Other Alnylam Pharmaceuticals trials

Trials by the same sponsor.

NCT07535606 — A Study to Evaluate ALN-4915 in Adult Healthy Volunteers · Phase 1 · recruiting
NCT07463846 — A Study to Evaluate ALN-2232 in Participants With Obesity · Phase 1, PHASE2 · recruiting
NCT07223203 — TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidos · Phase 3 · recruiting
NCT07465224 — A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus · Phase 2 · recruiting
NCT07358078 — DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02797847 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Alnylam Pharmaceuticals
Last refreshed: 21 September 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02797847.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing